ENVB - Enveric Biosciences, Inc.
1.98
-0.110 -5.556%
Share volume: 92,329
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.31%
PREVIOUS CLOSE
CHG
CHG%
$2.09
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-15-2024 | 08-12-2024 | 11-14-2024 | 03-28-2025 | 05-14-2025 | 08-14-2025 | 11-14-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 2.392 M | 1.813 M | 1.998 M | 3.091 M | 2.107 M | 2.479 M | 1.834 M | |
| Selling general and admin | 1.934 M | 1.298 M | 1.236 M | 1.986 M | 1.360 M | 1.219 M | 1.431 M | |
| Research and development | 458.155 K | 515.501 K | 762.717 K | 1.105 M | 746.371 K | 1.260 M | 402.417 K | |
| Total expenses | 2.477 M | 1.898 M | 2.083 M | 3.174 M | 2.188 M | 2.519 M | 1.874 M | |
| -23.39% | 9.76% | 52.35% | -31.08% | 15.15% | -25.61% | |||
| Operating income | -2.477 M | -1.898 M | -2.083 M | -3.174 M | -2.188 M | -2.519 M | -1.874 M | |
| Ebit | -2.467 M | -1.887 M | -2.083 M | -3.150 M | -2.185 M | -2.519 M | -1.874 M | |
| Pretax income | -2.455 M | -1.879 M | -2.084 M | -3.147 M | -2.185 M | -2.519 M | -1.874 M | |
| -23.45% | 10.89% | 51.03% | -30.58% | 15.30% | -25.62% | |||
| Income tax | 1.731 K | 0.000 | 0.000 | 7.199 K | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.457 M | -1.879 M | -2.084 M | -3.155 M | -2.185 M | -2.519 M | -1.874 M | |
| 23.51% | -10.89% | -51.37% | 30.74% | -15.30% | 25.62% |